Tempus AI will report its Q3 earnings on Nov. 2, with investors focused on its pending $1.5 billion acquisition of Personalis. Despite recent strong revenue growth and earnings beats, the stock has fallen over 20% in the past month. The upcoming report must demonstrate that Tempus' core business can sustain the acquisition while maintaining positive cash flow and adjusted EBITDA targets. Success could clarify the future value of the Personalis deal and boost investor confidence.
As Tempus AI prepares for its Nov. 2 earnings report, the stock is trading at USD 67.58 on Pluang, showing a modest 0.63% gain as of Oct 27, 2026 20:42 WIB. Despite recent price volatility, investor interest remains strong with 68% of order activity on Pluang being buys. Personalis shares, involved in the pending acquisition, are priced at USD 15.94 with a 0.38% increase, reflecting steady market attention ahead of the deal's potential impact.
Tempus AI has been upgraded to a higher-conviction Buy following resolution of concerns about MRD ownership and positive adjusted EBITDA. The acquisition of Personalis strengthens its MRD capabilities and pharma partnerships, while FDA approval of xT...
Tempus AI reported a strong 22% year-over-year revenue growth and projects revenues to reach $1.6 billion by 2026, driven by its AI-powered diagnostics and data licensing model. The company recently went public in June 2024, raising $411 million, and...
